Healthcare Industry News: Incyte
News Release - June 13, 2011
Tetragenetics Announces New CEO and Expands Board of DirectorsEstablishes Headquarters in Cambridge, MA
CAMBRIDGE, Mass.--(Healthcare Sales & Marketing Network)-- Tetragenetics Inc., a biotechnology company focused on the development of recombinant vaccines, announced today that Dr. Marco Cacciuttolo has been appointed President and Chief Executive Officer. The company also announced the appointment of Ben Machielse and Robert Gailus to the Board of Directors, as well as the establishment of its headquarters in Cambridge, Massachusetts.
“Marco brings a depth of experience and management expertise to our leadership team. We are thrilled that he has chosen to join Tetragenetics as the company moves to an exciting new stage of development and growth,” said R. Douglas Kahn, Chairman.
Dr. Cacciuttolo added, “The Tetragenetics technology is an exciting innovation with potential to dramatically accelerate vaccine discovery, improve efficacy, and reduce manufacturing costs. Building on the cumulative experience of the biopharmaceutical industry over the years, Tetragenetics is poised to enable a major leap forward for biological medicines.”
With over 18 years of experience in executive management and technical operations within the biotech and pharmaceutical industries, Dr. Cacciuttolo has occupied positions of increasing responsibility at MedImmune, Inc., Medarex, Inc. as the Vice President of Technical Operations, and most recently, as President and CEO of PERCIVIA LLC. Dr. Cacciuttolo received his Ph.D. in Biochemical Engineering from the University of Maryland and his B.Sc. in Biochemical Engineering from the Catholic University of Valparaiso, Chile.
Ben Machielse was recently Executive Vice President of Operations at MedImmune, Inc. Ben played a key role in leading all aspects of the manufacture of Synagis® and FluMist® (Influenza Virus Vaccine Live, Intranasal), developing and launching the H1N1 vaccine and managing relations with the government. During his distinguished career, Ben participated in the development and approval of seven biotechnology drugs.
A financial advisor to Ogden-CAP Associates, LLP, NY, Robert Gailus joins the board as an experienced venture investor. He was a founding member of Schroder Ventures/U.S., the venture affiliate of Schroders, London. As a venture capitalist, Bob has invested in more than 75 early-stage companies, including Celgene, Cell Therapeutics, Incyte Pharmaceuticals, and Neurogen.
“We are also pleased to now join the active Cambridge biotechnology community with the establishment of our new headquarters,” stated Dr. Cacciuttolo. “Cambridge attracts world-class talent, offers outstanding resources and is central to many exciting scientific advancements in our industry, so it was the clear choice for Tetragenetics.”
About Tetragenetics Inc.
Tetragenetics is creating the next generation of vaccines. The company’s proprietary technologies (TetraExpress™, PRiSM™, and G-Some™), are based upon Tetrahymena thermophila, a sophisticated microorganism that enables the development, manufacture, and delivery of new and improved vaccines to address long-standing and emerging threats to human and animal health. www.tetragenetics.com
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.